As revealed by the above-mentioned findings, the serum ApoB/ApoA1 ratio in CHB patients may be conducive to identifying high-risk patients for HCC or LC, such that LC and HCC can be early diagnosed and treated. This evidence concerns the gene APOA1 and hepatocellular carcinoma.